Risperidone Treatment of Children and Adolescents: Increased Risk of Extrapyramidal Side Effects?

Journal of Child and Adolescent Psychopharmacology

Volumn 5, Issue 1, 1995, Pages 49-67

  Mandoki, Miguel W ^a  

^a UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE;

ADOLESCENT; BIPOLAR DEPRESSION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG TOLERANCE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MENTAL DISEASE; PSYCHOSIS; REVIEW; SCHIZOPHRENIA;

EID: 0029014822     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.1995.5.49     Document Type: Article

References (74)

1. Akiskal HS: Dysthymic and cyclothymic depressions: Therapeutic considerations. J Clin Psychiatry 55(Suppl):46-52, 1994.
2. Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA: Clozapine-induced agranulocytosis. N Engl J Med 329:162-167, 1993.
3. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC, American Psychiatric Association, 1987.
4. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC, American Psychiatric Association, 1994.
5. Amminger GP, Resch F. Reimitz J. Friedrich MH: Nebenworkungen von clozapin in der therapie psychotischer zustandbilder bei jungendlichen: Eine retrospektive klinische studie. Z Kinder Jugendpsychiat 20:5-11, 1992.
6. Awouters F. Niemegeers CJE, Megens AAHP, Janssen PAJ: Functional interaction between serotonin S-2 and dopamine D-2 neurotransmission as revealed by selective antagonism of hyper-reactivity to tryptamine and apomorphine. J Pharmacol Exp Ther 254:945-951, 1990.
7. Barrickman L. Noyes R. Kuperman S. Schumacher E. Verda M: Treatment of ADHD with fluoxetine: A preliminary trial. J Am Acad Child Adolesc Psychiatry 30:762-767, 1991.
8. Bersani G. Bressa GM, MeCo G. Marini S. Pozzi F: Combined serotonin 5-HT2 and dopamine D-2 antagonism in schizophrenia: Clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R 64 766). Hum Psychopharmacol 5:225-231, 1990.
9. Birmaher B. Baker R. Hapur S. Quintana H. Ganguli R: Clozapine for the treatment of adolescents with schizophrenia. J Am Acad Child Psychiatr 31:160-164, 1992.
10. Blanz B. Schmidt MH: Clozapine for schizophrenia [letter]. J Am Acad Child Adolesc Psychiatry 32:223-224, 1993.
11. Borison RL, Pathiraja AD, Diamond BI, Meibach RC: Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 28:213-218, 1992a.
12. Borison RL, Diamond BI, Pathiraja AD, Meibach RC: Clinical overview of risperidone. In: Novel Atypical Antipsychotic Drugs. Edited by Meltzer HY. New York, Raven Press, 1992b, pp 223-239.
13. Boxer GH, Davidson J: More on clozapine [letter]. J Am Acad Child Adolesc Psychiatry 31:993, 1992.
14. Braun-Scharm H. Martinius J: EEC-Veränderungen und Anfalle unter Clozapinmidikation bei schizophrenen Jugendlichen. Z Kinder Jugenpsychiatr 19:164-169, 1991.
15. Caroli F. Baldacci-Epinette C. Ribeyre P: Depression and schizophrenia. Encephale 19:393-396, 1993.
16. Castelao JF, Ferreira L. Gelders YG, Heylen SLE: The efficacy of the D-2 and 5HT-2 antagonist risperidone (R 64766) in the treatment of chronic psychosis: An open dose-fmding study. Schizophr Res 2:411-415, 1989.
17. Ceskova E. Svestka J: Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 26:121-124, 1993.
18. Chouinard G. Amott W: Clinical review of risperidone. Can J Psychiatry 38(Suppl):S89-S95, 1993.
19. Chouinard G. Ross-Chouinard A. Annable L. Jones BD: The extrapyramidal symptom rating scale. Can J Neurol Sei 7:233, 1980.
20. Chouinard G. Jones B. Remington G. Bloom D. Addington D. MacEwan GW, Labelle A. Beauclair L. Amott W: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40, 1993.
21. Claus A. Bollen J. De-Cuyper H. Eneman M. Malfroid M. Peuskens J. Heylen S: Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multicentre double-blind comparative study. Acta Psychiatr Scand 85:295-305, 1992.
22. Cozza SJ, Edison DL: Risperidone in adolescents [letter]. J Am Acad Child Adolesc Psychiatry 33:1211, 1994.
23. Czyrak A. Jaros T. Moryl E. Maj J: Pharmacological effects of zotepine and other antipsychotics on the central 5-HT-2 receptors. Pharmacopsychiatry 26:53-58, 1993.
24. Desseilles M. Antoine J. Pietquin M. Burton P. Gelders Y. Heylen S: Risperidone in psychotic patients: An open dose-fmding study. Psychiatr Psychobiol 5:319-324, 1990.
25. Dwight MM, Keck PE, Stanton SP, Strakowski SM, McElroy SL: Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder. Lancet 344:544-555, 1994.
26. Ereshefsky L. Lacombe S: Pharmacological profile of risperidone. Can J Psychiatry 38(Suppl):S80-S88, 1993.
27. Frazier JA, Gordon CT, McKenna K. Lenane MC Jih D. Rapoport JL: An open trial of clozapine in 11 adolescents with childhood onset schizophrenia. J Am Acad Child Adolesc Psychiatry 33:658-663, 1994.
28. Freedman JE, Wirshing WC, Russell AT, Palmer-Bray M. Unutzer J: Absence status seizures during successful longterm clozapine treatment of an adolescent with schizophrenia. J Child Adolesc Psychopharmacol 4:53-62, 1994.
29. Gelders YG, Heylen SLE, Vanden-Bussche G. Reyntjens AJM, Janssen PAJ: Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry 23:206-211, 1990.
30. Gorden CT, Frazier JA, McKenna K. Gledd J. Zametkin A. Zahn T. Hommer D. Hong W. Kaysen D. Albus KE, Rapoport JL: Childhood-onset schizophrenia: An NIMH study in progress. Schizophr Bull 20:697-712, 1994.
31. Gunther W. Baghai T. Naber D. Spatz Kugler J: EEG-Veränderungen und Krampfanfalle wahrend der Behandlung mit Clozapin (Leponex). In: Clozapin: Pharmacokologie un Klinik eines atypischen Neuroleptikums-eine critische Bestandsaufhanme. Edited by Naber D. Muller-Spahn F. Stuttgart, Schattauer, 1992, pp 135-146.
32. Guy W: ECDEU Assessment Manual for Psychopharmacology, revised ed. Washington, DC, Department of Health Education and Welfare, 1976.
33. Heinrich K. Klieser E. Lehmann E. Kinzler E: Experimental comparison of the efficacy and compatibility of risperidone and clozapine in acute schizophrenia. In: Risperidone—Major Progress in Antipsychotic Patients. Proceedings of a Satellite Symposium at the 17th Congress of Collegium Internationale Neuro-Psychopharmacogicum, Kyoto, Japan, Sept 10-14, 1990. pp 37-39.
34. Hillert A. Maier W. Wetzel H. Benkert O: Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome: A functional approach. Pharmacopsychiatry 25:213-217, 1992.
35. Hopkins HS, Gelenberg AJ: Treatment of bipolar disorder: How far have we come? Psychopharmacol Bull 30:27-38, 1994.
36. Jacobsen LK, Walker MC, Edwards JE, Chappell PB, Woolston JL: Clozapine in the treatment of a young adolescent with schizophrenia. J Am Acad Child Adolesc Psychiatry 33:645-650, 1994.
37. Janssen PAJ, Niemegeers CJE, Awouters F. Schellekens KHL, Megens AAHP, Meert TF: Pharmacology of risperidone (R 64766), a new antipsychotic with serotonin S-2 and dopamine D-2 antagonistic properties. J Pharmacol Exp Ther 244:685-693, 1988.
38. Kane JM, Marder SR: Psychopharmacologic treatment of schizophrenia. Schizophr Bull 19:287-302, 1993 Kovacs M: Manual for the Children's Depression Inventory. North Tonawanda (NY), Multi-Health System Inc, 1992.
39. Krupp P. Barnes P: Clozapine associated agranulocytosis: Risk and aetiology. Br J Psychiatry 160(Suppl 17):38-40, 1992.
40. Levkovitch Y. Kaysar N. Kronnenberg Y. Hagai H. Gaoni B: Clozapine for schizophrenia [letter]. J Am Acad Child Adolesc Psychiatry 33:431, 1994.
41. Lieberman JA, Kane JM, Johns CA: Clozapine: Guidelines for clinical management. J Clin Psychiatry 50:329-338, 1989.
42. Lingjaerde O. Ahlfors UG, Bech P. Dencker SJ, Elgen K: The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 76(Suppl 334): 1-100, 1987.
43. Mandoki MW: Clozapine for adolescents with psychosis: Literature review and two case reports, J Child Adolesc Psychopharmacol 3:213-221, 1993.
44. Marder SR: Risperidone: Clinical development: North American results. Proceedings of the 18th Collegium International Neuro-Psychopharmacologicum Congress pp S20-S58, 1992.
45. Matsubara S. Matsubara R. Kusumi I. Koyama T. Yamashita I: Dopamine D-1, D-2 and serotonin-2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J Pharmacol Exp Ther 265:498-508, 1993.
46. Meco C. Bedini L. Bonifati V. Sonsini U: Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia. A single-blind cross-over study versus placebo. Curr Ther Res 46:876-883, 1989.
47. Meert TF, Awouters F: Central 5-HT-2 antagonists: A preclinical evaluation of a therapeutic potential. Acta Neuropsychiatr 2:101-106, 1990.
48. Meltzer HY: New drugs for the treatment of schizophrenia. Psychiatr Clin North Am 16:365-385, 1993.
49. Meltzer HY: Atypical antipsychotics. In: Psychopharmacology: The Fourth Generation of Progress. Edited by Meltzer HY, Bloom FE, Kupfer DJ. New York, Raven Press, 1995, pp 1277-1286.
50. Mesotten F. Suy E. Pietquin M. Burton P. Heylen S. Gelders Y: Therapeutic effect and safety of increasing doses of. risperidone (R 64766) in psychotic patients. Psychopharmacology 99:445-449, 1989.
51. Moller HJ, Pelzer E. Kissling W. Riehl T. Wernicke T: Efficacy and tolerability of a new antipsychotic compound (risperidone): Results of a pilot study. Pharmacopsychiatry 24:185-189, 1991.
52. Mozes T. Toren P. Chemauzan N. Mester R. Yoran-Hegesh R. Blumensohn R. Weizman A: Clozapine treatment in. very early onset schizophrenia. J Am Acad Child Adolesc Psychiatry 33:65-70, 1994.
53. Muller-Spahn F: Risperidone in the treatment of chronic schizophrenic patients: An international double-blind parallel group study versus haloperidol. Clin Neuropharm 15(Suppl):90A-91A, 1992.
54. Niemegeers CJE, Awouters F. Janssen PAJ: Involvement of serotonin in the action of antipsychotic drugs: Recent evidence with ritanserin and risperidone. Encephale 16:147-151, 1990.
55. Physicians Desk Reference, 49th Edition. Montvale (NJ), Medical Economics Data Production Company, 1995.
56. Porsolt RD: Serotonin: Neurotransmitter ‘a la mode’. Report on the Third International I.T.E.M.-LABO Symposium on Strategies in Psychopharmacology: Serotonin: Animal Models and Clinical Targets. Pharmacopsychiatry 26:20-24, 1993.
57. Purdon SE, Wilson L. Labelle A. Jones BDW: Riperidone in the treatment of pervasive developmental disorder. Can J Psychiatry 39:400-405, 1994.
58. Rapoport JL: Clozapine and child psychiatry [editorial]. J Child Adolesc Psychopharmacol 4:1-3, 1994.
59. Remington GJ: Clinical considerations in the use of risperidone. Can J Psychiatry 38(Suppl);S96-S100, 1993.
60. Remschmidt H. Schulz E. Martin PDM: An open trial of clozapine in 36 adolescents with schizophrenia. J Child Adolesc Psychopharmacol 4:31-41, 1994.
61. Sachdev P: Drug-induced movement disorders in institutionalized adults with mental retardation: Clinical characteristics and risk factors. Aust New Zealand J Psychiatry 26:242-248, 1992.
62. Schmidt MH, Trott GE, Blanz B. Nissen G: Clozapine medication in adolescents. In: Psychiatry: A World Perspective, Vol. 1 (Proceedings of the VIII World Congress of Psychiatry, Athens, 12-19 October 1989). Edited by Stefanis CN, Rabavilas AD, Soldatos CR. Amsterdam, Excerpta Medica, 1990, pp 1100-1104.
63. Seeman P: Atypical neuroleptics: Role of multiple receptors, endogenous dopamine, and receptor linkage. Acta Psychiatr Scand (Suppl) 82:14-20, 1990.
64. Shuwall M. Siris SG: Suicidal ideation in postpsychotic depression. Comprehens Psychiatry 35:132-134, 1994.
65. Siefen G. Remschmidt HG: Behandlungsergebnisse mit Clozapin beischizophrenen Jugendlichen. Z Kinder Jugendpsychiat 14:245-257, 1986.
66. Siris SG: Akinesia and postpsychotic depression: A difficult differential diagnosis. J Clin Psychiatry 48:240-243, 1987.
67. Siris SG, Adan F. Cohen M. Mande U J. Aronson A. Casey E: Postpsychotic depression and negative symptoms: An investigation of syndromal overlap. Am J Psychiatry 145:1532-1537, 1988.
68. Sleight AJ, Koek W. Bigg DCH: Binding of antipsychotic drugs at alpha (lA) and alpha (IB)-adrenoceptors: Risperidone is selective for the alpha (IB)-adrenoceptors. Eur J Pharmacol 238:407-410, 1993.
69. Towbin KE, Dykens EM, Pugliese RG: Clozapine for early developmental delays with childhood onset schizophrenia: Protocol and 15 month outcome. J Am Acad Child Adolesc Psychiatry 33:651-657, 1994.
70. United States Department of Health and Human Services, Center for Disease Control and Prevention, National Center for Health Statistics: International Classification of Diseases, Ninth Edition. Washington, DC, U.S. Government Printing Office, 1991.
71. Vanden-Borre R. Vermote R. Buttiens M. Thiry P. Dierick G. Geutjens J. Sieben G. Heylen S: Risperidone as add-on therapy in behavioral disturbances in mental retardation: A double-blind placebo-controlled cross-over study. Acta Psychiatr Scand 87:167-171, 1993.
72. Van Putten T. Marder SR: Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry 48(Suppl): 13-19, 1987.
73. Wechsler D: Manual for the Wechsler Intelligence Scale for Children, Third Edition. New York, Psychological Corporation, 1991.
74. Wechsler D: Manual for the Wechsler Intelligence Scale for Children: Revised, Third Edition. New York, Psychological Corporation, 1974.